<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003701</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066808</org_study_id>
    <secondary_id>E-1897</secondary_id>
    <nct_id>NCT00003701</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients With Bladder Cancer</brief_title>
  <official_title>A Phase III Randomized Trial of Either M-VAC or Paclitaxel + Carboplatin as Postoperative Adjuvant Therapy in Patients With Muscle-Invasive Transitional Cell Carcinoma of the Bladder at High-Risk for Relapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Eastern Cooperative Oncology Group</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells. It is not&#xD;
      yet known whether four-drug combination chemotherapy is more effective than two-drug&#xD;
      combination chemotherapy in treating bladder cancer.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of two combination&#xD;
      chemotherapy regimens in treating patients who have bladder cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Compare the recurrence rates and overall survival of patients treated with&#xD;
      postoperative adjuvant methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) to those&#xD;
      treated with combination paclitaxel and carboplatin for muscle invasive bladder cancer at&#xD;
      particularly high risk of relapse. II. Compare the relative toxicities of postoperative M-VAC&#xD;
      versus those encountered with postoperative paclitaxel and carboplatin. III. Compare the&#xD;
      quality of life scores during and following completion of treatment of patients in these two&#xD;
      treatment arms.&#xD;
&#xD;
      OUTLINE: This is a randomized study. Patients are stratified by N stage (N0 vs N+) and&#xD;
      performance status (0-1 vs 2). Patients are randomized to receive methotrexate, vinblastine,&#xD;
      doxorubicin, and cisplatin (arm I) or paclitaxel and carboplatin (arm II). Arm I: Patients&#xD;
      receive methotrexate IV push on days 1, 15, and 22; vinblastine IV push on days 2, 15, and&#xD;
      22; doxorubicin IV push on day 2; and cisplatin IV over 2 hours on day 2. Treatment repeats&#xD;
      every 28 days for 4 courses. Arm II: Patients receive paclitaxel IV over 3 hours on days 1&#xD;
      followed by carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 4&#xD;
      courses. Quality of life assessments are completed pretreatment, prior to course 3, 6 weeks&#xD;
      after the last dose of chemotherapy, and at 6, 12, and 24 months from the end of therapy.&#xD;
      Patients are followed every 3 months until year 2, every 6 months for years 2-5, and then&#xD;
      annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: There will be 490 patients accrued into this study within 2.6 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1999</start_date>
  <completion_date type="Actual">June 15, 2007</completion_date>
  <primary_completion_date type="Actual">August 2001</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">490</enrollment>
  <condition>Bladder Cancer</condition>
  <condition>Urethral Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinblastine sulfate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically confirmed transitional cell carcinoma of the&#xD;
        bladder or mixed histologies containing a component of transitional cell carcinoma Must&#xD;
        have undergone radical cystectomy and pelvic lymph node dissection within 12 weeks prior to&#xD;
        randomization No evidence of distant metastatic disease on pre- or postoperative&#xD;
        radiographic scans No positive surgical margins in the cystectomy specimen and no known&#xD;
        macroscopic residual disease left at time of cystectomy No bladder sparing surgery May have&#xD;
        undergone continent urinary diversion or neobladder procedure but must have recovered&#xD;
        completely from the effects of surgery Must have muscle-invasive disease on final&#xD;
        pathologic staging and have a primary tumor stage of pT4, any N, M0, or any pT, N+, M0, or&#xD;
        pT3b, any N, any M, and following a pelvic lymph node dissection have a pathologic nodal&#xD;
        stage of pN0 (only if pT3b or pT4), pN1, or pN2 Clinically unsuspected organ confined&#xD;
        prostate cancer found during cystoprostatectomy allowed&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: Any age Performance status: ECOG 0-2 Life expectancy: Not&#xD;
        specified Hematopoietic: WBC at least 3,500/mm3 Platelet count at least 100,000/mm3&#xD;
        Hepatic: Bilirubin no greater than 1.5 times upper limit of normal (ULN) SGOT no greater&#xD;
        than 2 times ULN Renal: Creatinine no greater than 1.7 mg/dL OR Creatinine clearance at&#xD;
        least 60 mL/min Cardiovascular: No second degree atrioventricular block or bundle branch&#xD;
        block Other: No history of prior malignancy in the past 5 years except basal or squamous&#xD;
        cell carcinoma of the skin or carcinoma in situ of the cervix No active infection requiring&#xD;
        antibiotics No history of allergic reaction to drugs utilizing the vehicle Cremophor Not&#xD;
        pregnant or nursing Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Recovered from all prior therapies Biologic therapy: No prior&#xD;
        biologic response modifier therapy No filgrastim (G-CSF) 24 hours pre- or post-chemotherapy&#xD;
        administration Chemotherapy: No prior systemic chemotherapy Endocrine therapy: Not&#xD;
        specified Radiotherapy: No prior radiotherapy as a component of bladder sparing therapy No&#xD;
        prior adjuvant radiotherapy for locally advanced disease with positive margins Surgery: See&#xD;
        Disease Characteristics Other: Prior intravesical therapy for superficial bladder cancer&#xD;
        allowed and recovered&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce J. Roth, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Atlanta (Decatur)</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Hospitals</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hunterdon Regional Cancer Center</name>
      <address>
        <city>Flemington</city>
        <state>New Jersey</state>
        <zip>08822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Jersey Hospital - Millville</name>
      <address>
        <city>Millville</city>
        <state>New Jersey</state>
        <zip>08332</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center at Virtua-Memorial Hospital Burlington County</name>
      <address>
        <city>Mount Holly</city>
        <state>New Jersey</state>
        <zip>08060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverview Medical Center</name>
      <address>
        <city>Red Bank</city>
        <state>New Jersey</state>
        <zip>07701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Overlook Hospital</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07902-0220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU School of Medicine's Kaplan Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hahnemann University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102-1192</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6838</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>April 22, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2004</study_first_posted>
  <last_update_submitted>December 30, 2018</last_update_submitted>
  <last_update_submitted_qc>December 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2019</last_update_posted>
  <keyword>stage III bladder cancer</keyword>
  <keyword>transitional cell carcinoma of the bladder</keyword>
  <keyword>urethral cancer associated with invasive bladder cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Urethral Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

